Health & Medical · Week of Nov 2, 2026
CVS split leads a week of health portfolio reshaping
CVS Health plans a split, Vantive sells hemodialysis assets and Waters closes a deal, as several companies reshape portfolios and report Q3 results.
Portfolio restructuring was the main thread this week. CVS Health said it intends to separate into two publicly traded companies, with completion expected in the first half of 2028. Vantive agreed to divest most of its hemodialysis business to Rockwell Medical to focus on home dialysis and critical care. Waters Corporation announced it has acquired MOBILion Systems alongside its third-quarter results.
Third-quarter reporting also featured. Waters raised its full-year 2026 guidance, and Syra Health reported its third consecutive profitable quarter. Orthocell posted what it says is its strongest month of U.S. Remplir sales. Elsewhere, Illumina was selected to sequence genomes for Singapore's SG-INSIGHT study, Elanco released a survey on pet health spending, and POMDOCTOR regained compliance with Nasdaq's bid price rule.
Waters Corporation
Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results
Waters Corporation reported third quarter 2026 revenue of $1.767 billion and adjusted EPS of $4.10, raised full-year guidance to $6.479 billion to $6.497 billion in revenue, and announced it has acquired MOBILion Systems, Inc. Organic revenue grew 9% as reported, and GAAP diluted EPS fell to $0.82 from $2.50, which the company attributes to acquisition-related and restructuring charges.
Syra Health
Syra Health Delivers Third Consecutive Profitable Quarter: Record Revenue of $2.6 Million, Up 52%, and 46.3% Gross Margin
Syra Health reported Q3 2026 revenue of $2,557,295, up 52%, and net income of $344,610, its third consecutive profitable quarter, with gross margin of 46.3%. The company says that following CMS approval of Syrenity for the ACCESS Model, it is recruiting Accountable Care Organizations to use Syrenity with partner HealthSync.
CVS Health
CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare
CVS Health said it intends to separate into two independent public companies: one comprising Aetna, CVS Caremark, CVS Specialty, Oak Street Health and Signify Health, and CVS Pharmacy, comprising approximately 9,000 pharmacies, mail pharmacy, MinuteClinic and Health100. The separation is expected in the first half of 2028, subject to conditions including final board approval and confirmation of tax-free treatment, with David Joyner and Prem Shah named as the respective CEOs.
Elanco Animal Health
October Consumer Research Confirms Pet Health Remains Non-Negotiable Household Priority
Elanco Animal Health released an October survey of 2,018 U.S. adults in which 93% of pet owners said they maintained or increased pet spending, and 7 percent of consumers said they would cut pet health spending under economic pressure. The survey also found 38% of pet owners have shifted medication purchasing outside the clinic, with a doctor's recommendation cited as the top reason to switch medications.
VANTIVE US HEALTHCARE LLC
Vantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell Medical
Vantive agreed to divest most of its hemodialysis assets, including concentrates, HD monitors, water treatment systems and its Medolla, Italy facility, to Rockwell Medical, with closing expected in mid-2027. The dialyzer portfolio, including Theranova, is excluded, and Vantive says the deal sharpens its focus on home dialysis and critical care.
Illumina, Inc.
Illumina selected to help bring precision medicine into everyday healthcare in Singapore
Illumina said it was selected through an international competitive tender to provide whole-genome sequencing for SG-INSIGHT, a cohort under Phase III of Singapore's National Precision Medicine programme expected to include about 450,000 individuals. The study aims to link genomic data with real-world health data and support genetic screening in Singapore's public healthcare system, though the release gives no start date.
Orthocell Limited
Orthocell Achieves Strongest Month of U.S. Remplir™ Sales Since Launch
Orthocell reported U.S. sales of 92 Remplir units in October 2026, generating AU$279,000, an 84% uplift on the Q1 FY27 monthly average of 50 units. The company attributes the increase to surgeon adoption, repeat use and expanded hospital access, and says it is expanding manufacturing capacity.
POMDOCTOR LIMITED
POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
POMDOCTOR LIMITED said Nasdaq confirmed on November 5, 2026 that it has regained compliance with the $1.00 minimum bid price requirement. The Nasdaq Hearings Panel hearing set for November 12, 2026 was cancelled, and its Class A shares will continue trading under "POM."
This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Times Beats reporting.